AGENDA

ALABAMA MEDICAID AGENCY
PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

February 5, 2020
9:00 a.m. – 12:00 p.m.

1. Opening remarks..........................................................Chair
2. Approval of November 6, 2019 P&T Committee Meeting minutes..........Chair
3. Pharmacy program update........................................Alabama Medicaid
4. Oral presentations by manufacturers/manufacturers’ representatives
   (prior to each respective class review)
5. Pharmacotherapy class re-reviews..................UMass Clinical Pharmacy Services
   • Central Alpha-Agonists – AHFS 240816
   • Direct Vasodilators – AHFS 240820
   • Peripheral Adrenergic Inhibitors – AHFS 240832
   • Hypotensive Agents, Miscellaneous – AHFS 240892
   • Alpha-Adrenergic Blocking Agents – AHFS 242000
   • Beta-Adrenergic Blocking Agents – AHFS 242400
   • Dihydropyridines – AHFS 242808
   • Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892
   • Angiotensin-Converting Enzyme Inhibitors – AHFS 243204
   • Angiotensin II Receptor Antagonists – AHFS 243208
   • Mineralocorticoid (Aldosterone) Receptor Antagonists – AHFS 243220
   • Renin Inhibitors – AHFS 243240
   • Loop Diuretics – AHFS 402808
   • Potassium-Sparing Diuretics – AHFS 402816
   • Thiazide Diuretics – AHFS 402820
   • Thiazide-Like Diuretics – AHFS 402824
   • Vasopressin Antagonists – AHFS 402828
   • Diuretics, Miscellaneous – AHFS 402892
6. Pharmacotherapy new drug re..........................UMass Clinical Pharmacy Services
   • Nuzyra® (omadacycline) – Tetracyclines: AHFS Class 081224
7. Results of voting announced................................................Chair
8. Next meeting dates
   • May 6, 2020
   • August 5, 2020
   • November 4, 2020
9. Adjourn